Dear guest!
article: Designer Therapeutic Proteinsformat: Adobe Acrobat PDF filecost: £
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
More info >>